VEECO INSTRUMENTS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VEECO INSTRUMENTS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $143.43M | Feb 21, 2018 |
| FY2017 | Sep 30, 2017 | $131.87M | Feb 21, 2018 |
| FY2017 | Jun 30, 2017 | $115.07M | Feb 21, 2018 |
| FY2017 | Mar 31, 2017 | $94.39M | Feb 21, 2018 |
| FY2017 | Dec 31, 2016 | $93.61M | Feb 21, 2018 |
| FY2017 | Sep 30, 2016 | $85.48M | Feb 21, 2018 |
| FY2017 | Jun 30, 2016 | $75.35M | Feb 21, 2018 |
| FY2017 | Mar 31, 2016 | $78.01M | Feb 21, 2018 |
| FY2016 | Dec 31, 2015 | $106.54M | Feb 22, 2017 |
| FY2016 | Sep 30, 2015 | $140.74M | Feb 22, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $265.41M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $304.01M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $285.06M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $263.15M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $242.27M | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | $56.85M | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | $49.14M | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | $41.89M | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | $46.42M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $44.97M | Feb 22, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.39M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $73.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($30.37M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $166.94M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $26.04M | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | ($102.0K) | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | $580.0K | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | ($8.30M) | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | ($567.0K) | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | ($32.87M) | Feb 22, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $66.98M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $69.94M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $60.30M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $56.71M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $22.57M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($39.58M) | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | ($415.50M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | ($71.87M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | ($120.16M) | May 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.64M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $124.51M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $112.85M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $103.57M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $88.68M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $78.99M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $90.56M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $97.76M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $81.99M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $81.02M | May 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.91M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $99.66M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $92.76M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $88.95M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $84.54M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $76.25M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $79.75M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $92.06M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $100.25M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $77.64M | May 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.49M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $63.82M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $61.67M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $108.48M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $67.74M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $43.02M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($7.42M) | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | ($37.74M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $34.99M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | ($23.84M) | May 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $18.11M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $27.93M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $24.60M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $40.64M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $6.80M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $10.87M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $12.65M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $24.27M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $11.48M | May 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.33B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.25B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.23B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.13B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $898.98M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $898.06M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $818.09M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $900.82M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $1.39B | May 1, 2019 |
| FY2017 | Dec 31, 2016 | $758.53M | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $440.29M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $480.81M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $556.60M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $550.36M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $461.35M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $489.69M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $443.58M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $463.04M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $547.38M | May 1, 2019 |
| FY2017 | Dec 31, 2016 | $163.94M | Feb 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $885.51M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $770.77M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $672.44M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $577.82M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $437.63M | Feb 14, 2025 |
| FY2023 | Dec 31, 2020 | $408.37M | Feb 16, 2024 |
| FY2022 | Dec 31, 2019 | $374.51M | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | $437.78M | Feb 18, 2022 |
| FY2020 | Dec 31, 2017 | $840.09M | Feb 22, 2021 |
| FY2019 | Dec 31, 2016 | $601.70M | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.96M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $214.96M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $214.96M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $181.94M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $181.94M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $181.94M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $181.94M | Feb 22, 2021 |
| FY2020 | Dec 31, 2018 | $184.30M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $307.13M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $114.91M | May 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($423.07M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($458.46M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($532.17M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($501.80M) | Feb 16, 2024 |
| FY2023 | Dec 31, 2021 | ($681.28M) | Feb 16, 2024 |
| FY2021 | Dec 31, 2020 | ($707.32M) | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | ($698.93M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | ($619.98M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | ($212.87M) | May 1, 2019 |
| FY2017 | Dec 31, 2016 | ($168.58M) | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $163.47M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $145.60M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $158.78M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $154.93M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $119.75M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $129.63M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $129.29M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $212.27M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $279.74M | May 1, 2019 |
| FY2017 | Dec 31, 2016 | $277.44M | Feb 21, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.01M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $276.20M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $274.94M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $274.66M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $229.44M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $321.12M | Feb 18, 2022 |
| FY2016 | Dec 31, 2016 | $1.19M | Feb 22, 2017 |
| FY2015 | Dec 31, 2015 | $1.53M | Feb 25, 2016 |
| FY2014 | Dec 31, 2014 | $1.85M | Feb 24, 2015 |
| FY2013 | Dec 31, 2013 | $2.14M | Feb 28, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 22, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 22, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 60.39M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 56.83M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 56.36M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 51.66M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | 50.65M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 49.72M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | 48.99M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | 48.02M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 48.14M | May 1, 2019 |
| FY2017 | Dec 31, 2016 | 40.59M | Feb 21, 2018 |